Application for clinical application of two new drugs of class 1.1 in Kelun pharmaceutical

According to the information from the State Food and Drug Administration on April 15, the application of ceftoren sodium phosphate for injection and ceftoren sodium for injection by Kelun Pharmaceutical Co., Ltd was accepted clinically, and the drugs applied for were all new drugs of class 1.1 In the 2012 annual report of Kelun Pharmaceutical Co., Ltd., it was mentioned for the first time that the "development and industrialization of ceftoren axetil sodium phosphate", a major new drug creation project during the 12th Five Year Plan, was approved by the Ministry of science and technology, achieving a breakthrough in undertaking the national science and technology program Industry insiders pointed out that the drugs declared by Kelun pharmaceutical industry this time are ceftoren products At present, most of them are ceftoren pivoxil in the market, which is an innovative product of the third generation of cephalosporins For the above-mentioned declared drugs, the directors and secretaries Office of Kelun pharmaceutical said that there is still a long way to go from the clinical application to the approval of the declared class a new drugs, which is also part of the overall R & D project of the company Since 2013, the R & D of new drugs in Kelun pharmaceutical industry has been promoted rapidly, and the applied drugs are mostly generic drugs in digestive tract, tumor and other fields According to the data disclosed by Kelun pharmaceutical, there are more than 240 new drug projects under research, and the R & D progress has been scheduled to 2020.